Clinical Trial Application for Baiyunshan's Xuhanting Granules in Pediatric Recurrent Respiratory Infections Receives Approval

Stock News

Mar 16

Baiyunshan (00874) has announced that its subsidiary, Guangzhou Baiyunshan Qixing Pharmaceutical Co., Ltd., recently received a Drug Clinical Trial Approval Notice from the National Medical Products Administration. The approval is for adding a new indication for Xuhanting Granules. Xuhanting Granules are known for their effects in replenishing qi and nourishing yin, as well as consolidating the exterior and stopping sweating. They are currently indicated for spontaneous sweating and night sweats due to qi and yin deficiency, including cases in children. As an already-marketed traditional Chinese medicine compound preparation, this application seeks approval to conduct clinical trials for its use in treating recurrent respiratory infections in children.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1120935628"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1120935628\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1120935628?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-16 18:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1120935628","market":"us","top_or_hot":-1,"title":"Clinical Trial Application for Baiyunshan's Xuhanting Granules in Pediatric Recurrent Respiratory Infections Receives Approval","media":"Stock News","content":"<p>Baiyunshan (00874) has announced that its subsidiary, Guangzhou Baiyunshan Qixing Pharmaceutical Co., Ltd., recently received a Drug Clinical Trial Approval Notice from the National Medical Products Administration. The approval is for adding a new indication for Xuhanting Granules. Xuhanting Granules are known for their effects in replenishing qi and nourishing yin, as well as consolidating the exterior and stopping sweating. They are currently indicated for spontaneous sweating and night sweats due to qi and yin deficiency, including cases in children. As an already-marketed traditional Chinese medicine compound preparation, this application seeks approval to conduct clinical trials for its use in treating recurrent respiratory infections in children.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clinical Trial Application for Baiyunshan's Xuhanting Granules in Pediatric Recurrent Respiratory Infections Receives Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClinical Trial Application for Baiyunshan's Xuhanting Granules in Pediatric Recurrent Respiratory Infections Receives Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-16 18:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Baiyunshan (00874) has announced that its subsidiary, Guangzhou Baiyunshan Qixing Pharmaceutical Co., Ltd., recently received a Drug Clinical Trial Approval Notice from the National Medical Products Administration. The approval is for adding a new indication for Xuhanting Granules. Xuhanting Granules are known for their effects in replenishing qi and nourishing yin, as well as consolidating the exterior and stopping sweating. They are currently indicated for spontaneous sweating and night sweats due to qi and yin deficiency, including cases in children. As an already-marketed traditional Chinese medicine compound preparation, this application seeks approval to conduct clinical trials for its use in treating recurrent respiratory infections in children.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0183","symbol_name":"MSCI概念","start_time":0,"source_url":"","article_id":"1120935628","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1120935628","pubTimestamp":1773657311,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Baiyunshan (00874) has announced that its subsidiary, Guangzhou Baiyunshan Qixing Pharmaceutical Co., Ltd., recently received a Drug Clinical Trial Approval Notice from the National Medical Products...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600332":"白云山","BK0183":"MSCI概念","BK0188":"融资融券","BK0097":"医药电商","BK1191":"制药","BK1515":"抗疫概念","BK0096":"民营医院","BK0012":"证金概念","BK1521":"挪威政府全球养老基金持仓","BK0175":"白马股","BK0196":"行业龙头","BK1606":"中医药概念","BK0070":"员工持股","BK0028":"国家队","00874":"白云山","BK0239":"医药制造","BK1197":"保健护理产品经销商"},"translate_title":"白云山徐寒亭颗粒小儿反复呼吸道感染临床试验申请获批","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600332":1,"00874":1},"content_text":"Baiyunshan (00874) has announced that its subsidiary, Guangzhou Baiyunshan Qixing Pharmaceutical Co., Ltd., recently received a Drug Clinical Trial Approval Notice from the National Medical Products Administration. The approval is for adding a new indication for Xuhanting Granules. Xuhanting Granules are known for their effects in replenishing qi and nourishing yin, as well as consolidating the exterior and stopping sweating. They are currently indicated for spontaneous sweating and night sweats due to qi and yin deficiency, including cases in children. As an already-marketed traditional Chinese medicine compound preparation, this application seeks approval to conduct clinical trials for its use in treating recurrent respiratory infections in children.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}